Paid Clinical Trials Concord
Discover 246 paid clinical trials in Concord, New Hampshire. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
LuminopiaClinical Data Registry of Amblyopia Patients on Luminopia Treatment
Sponsor:
Luminopia
Location:
Code:
NCT06429280
Conditions
Amblyopia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
N/A this is an observational study of Standard of Care
Regional RadiotherapyRegional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Sponsor:
Canadian Cancer Trials Group
Location:
Code:
NCT03488693
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 35+
Healthy Volunteers: Not accepted
Interventions
Radiation
No Radiation
Engagement EnhancementEnhancing Engagement by Integrating Goals and Concerns That Matter to Patients
Sponsor:
Dartmouth-Hitchcock Medical Center
Location:
Code:
NCT06898593
Conditions
Anxiety Disorders
Depression Disorders
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Collaborative care model with clinical decision support system
Collaborative care model
Observational StudyPrevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Sponsor:
Ensoma
Location:
Code:
NCT06605378
Conditions
Chronic Granulomatous Disease (CGD)
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Targeted TreatmentTargeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT06031688
Conditions
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Lymphoscintigraphy
Magnetic Resonance Imaging
Ramucirumab
Interested in new trials?
Get alerts for new trials in your area by subscribing now
T-DM1 vs. THATEMPT 2.0: Adjuvant T-DM1 Vs TH
Sponsor:
Dana-Farber Cancer Institute
Location:
Code:
NCT04893109
Conditions
Breast Cancer
HER2-positive Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
trastuzumab-emtansine
Trastuzumab SC
Paclitaxel
Green TeaTo Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04597359
Conditions
Prostate Carcinoma
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Interventions
Placebo Administration
Quality-of-Life Assessment
Questionnaire Administration
Sinecatechins
Darolutamide & Hormone TherapyTwo Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Sponsor:
NRG Oncology
Location:
Code:
NCT05050084
Conditions
Prostate Adenocarcinoma
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bicalutamide
Buserelin
Darolutamide
Degarelix
Flutamide
Systemic TherapyStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT03678025
Conditions
Castration Levels of Testosterone
Metastatic Prostatic Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Abiraterone
Bicalutamide
Degarelix
Docetaxel
Flutamide
FDA Approved DrugsTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Sponsor:
American Society of Clinical Oncology
Location:
Code:
NCT02693535
Conditions
Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Palbociclib
Sunitinib
Temsirolimus
Trastuzumab and Pertuzumab
Vemurafenib and Cobimetinib